Cellerant Therapeutics (CTI) has been awarded additional funding valued at $16.7M by the Biomedical Advanced Research and Development Authority (BARDA) Read more…
CLT-008, an allogeneic cell-based therapy, is under development to provide hematopoietic support following high-dose chemotherapy or radiation exposure Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.